These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 30336989)

  • 1. Alzheimer Disease.
    Morley JE; Farr SA; Nguyen AD
    Clin Geriatr Med; 2018 Nov; 34(4):591-601. PubMed ID: 30336989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deciphering the genesis and fate of amyloid beta-protein yields novel therapies for Alzheimer disease.
    Selkoe DJ
    J Clin Invest; 2002 Nov; 110(10):1375-81. PubMed ID: 12438432
    [No Abstract]   [Full Text] [Related]  

  • 3. Identifying cost-effective predictive rules of amyloid-β level by integrating neuropsychological tests and plasma-based markers.
    Haghighi M; Smith A; Morgan D; Small B; Huang S
    J Alzheimers Dis; 2015; 43(4):1261-70. PubMed ID: 25147105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease.
    Lim YY; Maruff P; Pietrzak RH; Ames D; Ellis KA; Harrington K; Lautenschlager NT; Szoeke C; Martins RN; Masters CL; Villemagne VL; Rowe CC;
    Brain; 2014 Jan; 137(Pt 1):221-31. PubMed ID: 24176981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cognitive consequences of high Aβ amyloid in mild cognitive impairment and healthy older adults: implications for early detection of Alzheimer's disease.
    Lim YY; Ellis KA; Harrington K; Kamer A; Pietrzak RH; Bush AI; Darby D; Martins RN; Masters CL; Rowe CC; Savage G; Szoeke C; Villemagne VL; Ames D; Maruff P;
    Neuropsychology; 2013 May; 27(3):322-332. PubMed ID: 23688214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomarkers, ketone bodies, and the prevention of Alzheimer's disease.
    VanItallie TB
    Metabolism; 2015 Mar; 64(3 Suppl 1):S51-7. PubMed ID: 25468143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. β-Amyloidosis and neurodegeneration in Alzheimer disease: who's on first?
    Knopman DS
    Neurology; 2014 May; 82(20):1756-7. PubMed ID: 24748669
    [No Abstract]   [Full Text] [Related]  

  • 8. Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study.
    Dubois B; Epelbaum S; Nyasse F; Bakardjian H; Gagliardi G; Uspenskaya O; Houot M; Lista S; Cacciamani F; Potier MC; Bertrand A; Lamari F; Benali H; Mangin JF; Colliot O; Genthon R; Habert MO; Hampel H;
    Lancet Neurol; 2018 Apr; 17(4):335-346. PubMed ID: 29500152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Understanding the role of progranulin in Alzheimer's disease.
    D'Alton S; Lewis J
    Nat Med; 2014 Oct; 20(10):1099-100. PubMed ID: 25295938
    [No Abstract]   [Full Text] [Related]  

  • 10. What's next for Alzheimer treatment?: while Aβ isn't out of the picture yet, several other therapeutic routes are being explored.
    Schwartz A
    Ann Neurol; 2013 Apr; 73(4):A7-9. PubMed ID: 24643982
    [No Abstract]   [Full Text] [Related]  

  • 11. Synergistic interaction between amyloid and tau predicts the progression to dementia.
    Pascoal TA; Mathotaarachchi S; Shin M; Benedet AL; Mohades S; Wang S; Beaudry T; Kang MS; Soucy JP; Labbe A; Gauthier S; Rosa-Neto P;
    Alzheimers Dement; 2017 Jun; 13(6):644-653. PubMed ID: 28024995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease.
    Engler H; Forsberg A; Almkvist O; Blomquist G; Larsson E; Savitcheva I; Wall A; Ringheim A; Långström B; Nordberg A
    Brain; 2006 Nov; 129(Pt 11):2856-66. PubMed ID: 16854944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biomarker-driven therapeutic management of Alzheimer's disease: establishing the foundations.
    Cummings J; Zhong K
    Clin Pharmacol Ther; 2014 Jan; 95(1):67-77. PubMed ID: 24105258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The behavioral, pathological and therapeutic features of the senescence-accelerated mouse prone 8 strain as an Alzheimer's disease animal model.
    Cheng XR; Zhou WX; Zhang YX
    Ageing Res Rev; 2014 Jan; 13():13-37. PubMed ID: 24269312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alzheimer disease therapy: can the amyloid cascade be halted?
    Golde TE
    J Clin Invest; 2003 Jan; 111(1):11-8. PubMed ID: 12511580
    [No Abstract]   [Full Text] [Related]  

  • 16. Refining the understanding of typical Alzheimer disease.
    Jessen F
    Nat Rev Neurol; 2019 Nov; 15(11):623-624. PubMed ID: 31506592
    [No Abstract]   [Full Text] [Related]  

  • 17. Predicting Alzheimer disease with β-amyloid imaging: results from the Australian imaging, biomarkers, and lifestyle study of ageing.
    Rowe CC; Bourgeat P; Ellis KA; Brown B; Lim YY; Mulligan R; Jones G; Maruff P; Woodward M; Price R; Robins P; Tochon-Danguy H; O'Keefe G; Pike KE; Yates P; Szoeke C; Salvado O; Macaulay SL; O'Meara T; Head R; Cobiac L; Savage G; Martins R; Masters CL; Ames D; Villemagne VL
    Ann Neurol; 2013 Dec; 74(6):905-13. PubMed ID: 24448836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The neurobiology of Alzheimer disease defined by neuroimaging.
    Masdeu JC; Kreisl WC; Berman KF
    Curr Opin Neurol; 2012 Aug; 25(4):410-20. PubMed ID: 22766722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alzheimer's disease: Unique markers for diagnosis & new treatment modalities.
    Aggarwal NT; Shah RC; Bennett DA
    Indian J Med Res; 2015 Oct; 142(4):369-82. PubMed ID: 26609028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of amyloid beta-protein in Alzheimer's disease.
    Liddell M; Owen MJ
    Lancet; 1992 Oct; 340(8823):851. PubMed ID: 1357270
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.